Viewing nowRegaba 50 mg (Pregabalin)
Pregabalin 50mg
Tablet · Prescription medication
Withus Pharmaceutical Co., Ltd.

MFDS item code 202002265 · Approved 2020.03.31 · Insurance code 660703400
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used to relieve peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for patients with epilepsy during partial seizures. Additionally, it helps alleviate pain caused by fibromyalgia. Therefore, it is effective in treating various nerve-related disorders.
This medicine is administered orally, with or without food, as pregabalin in 2 divided doses per day. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at a starting dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at a starting dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: This medicine may be administered at a starting dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a Starting dose (mg/day) | Maximum dose (mg/day) | Dosing regimen ≥60 | 150 | 600 | BID or TID ≥30-<60 | 75 | 300 | BID or TID ≥15-<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age or adolescent patients aged 12-17 years because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors; therefore, if symptoms of depression or mood changes occur during treatment, medical personnel should be notified immediately. Patients with an allergy to the ingredients of this medication should not take it. Diabetic patients may experience weight gain while taking this medication, which may require dosage adjustments of blood sugar control medications. If allergic reactions such as angioedema occur, the medication should be discontinued immediately, and consultation with medical personnel is necessary. Elderly patients should be cautious as dizziness or drowsiness may increase while taking this medication; extra caution is especially needed during the initial treatment phase. This medication may cause blurred vision or changes in vision; if symptoms occur, consultation with medical personnel is necessary. Discontinuation of this medication may result in withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so abrupt discontinuation should be avoided. There is a risk of drug abuse, so patients with a history of substance abuse should be particularly cautious while taking this medication. Patients with impaired kidney function may require dose adjustments. Patients with heart conditions should exercise caution while taking this medication. When this medication is taken together with opioid analgesics, the central nervous system depressant effects may be increased, so caution is required. Patients with compromised respiratory function or the elderly are at risk of severe respiratory depression, so consultation with medical personnel is important. In early pregnancy, there is a risk of fetal malformations, so women who are pregnant or planning to become pregnant should only take this medication after consulting with medical personnel and should use effective contraception. Breastfeeding women should consult with medical personnel regarding breastfeeding since this medication may be transmitted in breast milk. Caution is advised when engaging in dangerous activities such as driving or operating machinery, as dizziness or drowsiness may occur after taking this medication. In case of overdose, immediate medical attention should be sought, and dialysis may be performed if necessary. Keep out of reach of children, and do not transfer to other containers for safety. This medication may interact with other central nervous system depressants, so patients should inform medical personnel of any other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is advisable to keep it at room temperature between 1 degree and 30 degrees Celsius to maintain its effectiveness.
Pale yellow oval-shaped tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 50mg
Tablet · Prescription medication
Withus Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.